Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFPMA Outlines Plan For Fighting Counterfeit Drugs

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - The threat of counterfeit anti-infective drugs is rising rapidly, even as pharmaceutical companies, regulators and industry associations develop new strategies to deal with the problem

You may also be interested in...



India Says Counterfeit Drugs Should Be Handled By WTO - Not WHO

MUMBAI - Years of strong opposition from the Indian government, bolstered by recent support in that effort by some Latin American, African and South-East Asian countries, has exerted pressure on the World Health Assembly to establish a working group to handle the controversy surrounding the definition of "substandard" and "counterfeit" drugs

Chinese Distributor Of Counterfeit Pharmaceuticals Sentenced To Prison For 78 Months, $1.286 Million In Restitution To Pfizer And Lilly

SHANGHAI - The 5th Circuit U.S. Court of Appeals re-sentenced Kevin Xu, owner of Pacific Orient International, a pharmaceutical distributor in China, to prison for conspiring to distribute counterfeit and misbranded drugs, United States Attorney José Angel Moreno announced April 23

Global Giants Like Pfizer In Better Position To Tackle Counterfeiting

HONG KONG - Drug companies are stepping up efforts to fight counterfeit products that are emerging around the world as potential profits grow and penalties, compared to those associated with dealing in illegal narcotics, are relatively low

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel